BioSpace News Archive

Persica Pharmaceuticals Ltd, a clinical stage pharmaceutical company developing PP353, a unique injectable antibiotic, to treat chronic low back pain associated with bone oedema announces that it has successfully completed the first stage of a Phase Ib clinical trial to evaluate the safety, tolerability and pharmacokinetics of PP353.

NovaBay® Pharmaceuticals, Inc., a pharmaceutical company focusing on commercializing Avenova for the eye care market, announces an agreement with Okra Limited to distribute their Zocular dry eye products alongside Avenova in NovaBay’s physician-dispensed sales channel.

Adagene Inc., a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based immunotherapies, announced that it has entered into a third clinical trial collaboration and supply agreement with Merck.

Compugen Ltd., a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, announced that a bispecific antibody of AstraZeneca derived from COM902, Compugen’s high affinity anti-TIGIT antibody, will advance into clinical development.

CollPlant today announced financial results for the second quarter ended June 30, 2021 and provided an update on the Company’s business developments.

Noteworthy growth in the incidences of neurological disorders and autoimmune diseases across the globe is projected to help in the expansion of the global intravenous immunoglobulin market, according to a new study published by TMR.

During the 2nd quarter we significantly ramped up our pre commercial activities in the US following the strengthening of the team announced in Q1.

InDex Pharmaceuticals Holding AB announced that the company will conduct a clinical pharmacokinetic study with cobitolimod in Sweden.

Otonomy, Inc. today announced the appointment of Jill Broadfoot to its board of directors.

Visus Therapeutics Inc. announced it has entered into a worldwide exclusive licensing agreement with Cella Therapeutics to develop an array of investigational ophthalmic therapies to treat glaucoma and age-related macular degeneration, two of the leading causes of blindness globally.